Y-mAbs Therapeutics, Inc.984241109US984241109507/11/2025To approve, on a non-binding advisory vote basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES590000.0000000FOR590000.000000FORJazz Pharmaceuticals plcG50871105IE00B4Q5ZN4707/24/2025To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals pic's named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES151698.0000000FOR151698.000000FORWave Life Sciences Ltd.Y95308105SG999901471608/05/2025To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTES78972.0000000FOR78972.000000FORWave Life Sciences Ltd.Y95308105SG999901471608/05/2025To approve, on a non-binding, advisory basis only, the frequency of holding future shareholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES78972.0000000ONE YEAR78972.000000FORReplimune Group, Inc.76029N106US76029N106309/03/2025To approve, on a non-binding advisory basis, the compensation of Replimune Group, Inc.'s named executive officers for the fiscal year ended March 31, 2025.SECTION 14A SAY-ON-PAY VOTES534602.0000000FOR534602.000000FORRoivant Sciences Ltd.G76279101BMG76279101709/10/2025To cast a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES2084636.0000000AGAINST2084636.000000AGAINSTAkero Therapeutics, Inc.00973Y108US00973Y108212/02/2025To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger.SECTION 14A SAY-ON-PAY VOTES359445.0000000FOR359445.000000FORMerus N.V.N5749R100NL001160626412/09/2025Non-binding advisory proposal to approve certain compensation arrangementsSECTION 14A SAY-ON-PAY VOTES139864.0000000AGAINST139864.000000AGAINSTExact Sciences Corporation30063P105US30063P105702/20/2026Proposal to approve, on an advisory (nonbinding) basis, the compensation that may be paid or become payable to Exact Sciences Corporation's named executive officers that is based on or otherwise related to the Merger Agreement and the transactions contemplated by the Merger Agreement (the "Compensation Proposal").SECTION 14A SAY-ON-PAY VOTES80420.0000000AGAINST80420.000000AGAINSTIntuitive Surgical, Inc.46120E602US46120E602304/30/2026To approve, by advisory vote, the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES50939.0000000FOR50939.000000FOREli Lilly and Company532457108US532457108305/04/2026Approval, on an advisory basis, of the compensation paid to the company's named executive officers.SECTION 14A SAY-ON-PAY VOTES6121.0000000FOR6121.000000FORBristol-Myers Squibb Company110122108US110122108305/05/2026Advisory Vote to Approve the Compensation of our Named Executive OfficersSECTION 14A SAY-ON-PAY VOTES708678.0000000FOR708678.000000FORInsmed Incorporated457669307US457669307505/13/2026An advisory vote on the 2025 compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES136763.0000000FOR136763.000000FORCelcuity Inc.15102K100US15102K100705/14/2026To approve, on an advisory basis, named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES178753.0000000FOR178753.000000FORUltragenyx Pharmaceutical Inc.90400D108US90400D108105/14/2026Advisory (non-binding) vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES1116253.0000000FOR1116253.000000FORVera Therapeutics, Inc.92337R101US92337R101405/21/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES1440942.0000000FOR1440942.000000FOREstablishment Labs Holdings Inc.G31249108VGG31249108405/22/2026To approve, on an advisory basis, the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTES762.0000000FOR762.000000FORCytokinetics, Incorporated23282W605US23282W605705/27/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES53240.0000000FOR53240.000000FORDexCom, Inc.252131107US252131107405/27/2026To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2025.SECTION 14A SAY-ON-PAY VOTES242676.0000000FOR242676.000000FORAcadia Pharmaceuticals Inc.004225108US004225108405/29/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES1855.0000000FOR1855.000000FORBioMarin Pharmaceutical Inc.09061G101US09061G101306/02/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES535330.0000000FOR535330.000000FORXenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To approve, on an advisory basis, the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTES237435.0000000FOR237435.000000FORXenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To approve, on an advisory basis, the frequency of future shareholder advisory votes to approve the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTES237435.0000000ONE YEAR237435.000000FOREdgewise Therapeutics, Inc.28036F105US28036F105706/04/2026Conduct an advisory vote on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES158588.0000000FOR158588.000000FORNektar Therapeutics640268306US640268306306/04/2026To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote).SECTION 14A SAY-ON-PAY VOTES225040.0000000FOR225040.000000FORSavara Inc.805111101US805111101606/04/2026To approve, on an advisory basis, the compensation of our named executives.SECTION 14A SAY-ON-PAY VOTES731.0000000FOR731.000000FORTango Therapeutics, Inc.87583X109US87583X109006/04/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES207667.0000000FOR207667.000000FORAxsome Therapeutics, Inc.05464T104US05464T104306/05/2026To approve, by non-binding advisory vote, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES78787.0000000FOR78787.000000FORDyne Therapeutics, Inc.26818M108US26818M108006/05/2026To vote, on an advisory basis, to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES636362.0000000FOR636362.000000FORCogent Biosciences, Inc.19240Q201US19240Q201206/09/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES936438.0000000FOR936438.000000FORImmunome, Inc.45257U108US45257U108806/09/2026To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES836121.0000000FOR836121.000000FORImmunome, Inc.45257U108US45257U108806/09/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES836121.0000000ONE YEAR836121.000000FORCompass Therapeutics, Inc.20454B104US20454B104406/10/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES167441.0000000FOR167441.000000FORCompass Therapeutics, Inc.20454B104US20454B104406/10/2026To approve, on a non-binding, advisory basis, the holding of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES167441.0000000ONE YEAR167441.000000FORPraxis Precision Medicines, Inc.74006W207US74006W207006/10/2026To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2026 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.SECTION 14A SAY-ON-PAY VOTES26187.0000000FOR26187.000000FORArcus Biosciences, Inc.03969F109US03969F109306/11/2026To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES434868.0000000FOR434868.000000FORNatera, Inc.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES1550280.0000000FOR1550280.000000FORNatera, Inc.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES1550280.0000000ONE YEAR1550280.000000FORMirum Pharmaceuticals, Inc.604749101US604749101306/15/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES369.0000000FOR369.000000FORVaxcyte, Inc.92243G108US92243G108506/15/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES337.0000000FOR337.000000FORIDEAYA Biosciences, Inc.45166A102US45166A102506/16/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; andSECTION 14A SAY-ON-PAY VOTES368545.0000000FOR368545.000000FORDisc Medicine, Inc.254604101US254604101106/18/2026To approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES14781.0000000FOR14781.000000FORNextCure, Inc.65343E207US65343E207206/18/2026Approval, on an advisory basis, of the compensation paid by Company to its named executive officers.SECTION 14A SAY-ON-PAY VOTES222654.0000000FOR222654.000000FORORIC Pharmaceuticals, Inc.68622P109US68622P109306/18/2026To approve, on an advisory basis, executive compensation.SECTION 14A SAY-ON-PAY VOTES330206.0000000FOR330206.000000FORORIC Pharmaceuticals, Inc.68622P109US68622P109306/18/2026To approve, on an advisory basis, the frequency of future advisory votes on executive compensation.SECTION 14A SAY-ON-PAY VOTES330206.0000000ONE YEAR330206.000000FORSupernus Pharmaceuticals, Inc.868459108US868459108906/18/2026To approve, on a non-binding basis, the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTES568124.0000000FOR568124.000000FORBridgeBio Pharma, Inc.10806X102US10806X102806/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES153183.0000000FOR153183.000000FORBridgeBio Pharma, Inc.10806X102US10806X102806/22/2026To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES153183.0000000ONE YEAR153183.000000FORAxogen, Inc.05463X106US05463X106306/23/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement.SECTION 14A SAY-ON-PAY VOTES145597.0000000FOR145597.000000FORRhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2026Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTES164965.0000000AGAINST164965.000000AGAINSTUnited Therapeutics Corporation91307C102US91307C102706/26/2026Advisory resolution to approve executive compensation.SECTION 14A SAY-ON-PAY VOTES87641.0000000FOR87641.000000FOR